Disclosure: Conran has received grants from the Sao Paulo Research Foundation and Novartis AG; and participated in data safety monitoring or advisory boards for Novo Nordisk. Rees has participated on ...
Eleven new molecular drug targets receive approval in 2025, expanding treatment options for rare diseases, cancer, and infectious diseases.
Savita (42), a schoolteacher, visited my OPD with swollen fingers, aching wrists, and stiffness that made it difficult to ...
The Acting Chief Executive Officer of the proposed National Institute for Public Health and Infectious Diseases, Zaria, Kaduna State, Dr Dalhatu Aminu, has faulted the opposition to the bill ...
Greetings, and welcome to the Nuvectis Pharma Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Ron Bentsur, ...
Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy. In this large-scale, double-blind trial, 80 ...
Psoriasis pathobiology centers on TNF-α/IL-23/IL-17–driven inflammation with frequent obesity, diabetes, dyslipidemia, cardiovascular disease, and IBD ...
Medical researchers are warning that vitamin D deficiency — affecting approximately 40 percent of American adults — is contributing to a hidden epidemic of immune dysfunction, bone deterioration, ...
Welcome to Regeneron's conference call to discuss its C5 Complement Development Program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...
Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, IgA nephropathy (IgAN). In a phase 3 trial of adults who are at risk of ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. In general, the most common type of ...
The FDA made waves with its recent announcement that a single well-controlled Phase 3 study would suffice for a drug submission, replacing the previous standard of two pivotal studies. This past week, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results